Current view and status of the treatment of lower urinary tract symptoms and neurogenic lower urinary tract dysfunction

BJU International, Supplement

Volumn 85, Issue 2, 2000, Pages 25-30

  Kakizaki, H ^a   Koyanagi, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN; TERAZOSIN; URAPIDIL;

ADULT; AGED; BLADDER FUNCTION; CHINESE MEDICINE; ELECTROSTIMULATION; FEMALE; HUMAN; MALE; NERVE BLOCK; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; URINARY TRACT DISEASE;

EID: 0034070203     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.2000.00060.x     Document Type: Review

References (33)

1. 1 Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469-71
2. 2 Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9
3. 3 Serels S, Stein M. Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn 1998; 17: 31-6
4. 4 Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993; 42: 36-41
5. 5 Lepor H, Theune C. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. J Urol 1995; 154: 116-8
6. 6 Sullivan J, Abrams P. Alpha-adrenoceptor antagonists in neurogenic lower urinary tract dysfunction. Urology 1999; 53 (Suppl 3A): 21-8
7. 7 Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 1998; 81 (Suppl 1): 29-33
8. 8 Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986; 136: 1-4
9. 1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999; 161: 635-40
10. 1-adrenoceptors and uroselectivity. Prostate 1997; 30: 202-15
11. 11 Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255-63
12. 12 Ameda K, Sullivan MP, Yalla SV. Unobstructed male patients with lower urinary tract symptoms: Urodynamic characterization of pathophysiology. J Urol 1998; 159 (Suppl): 119
13. 13 Madersbacher S, Pycha A, Schatzl G, Mian C, Klingler CH, Marberger M. The aging lower urinary tract: a comparative urodynamic study of men and women. Urology 1998; 51: 206-12
14. 14 van Mastrigt R. Age dependence of urinary bladder contractility. Neurourol Urodyn 1992; 11: 315-7
15. 15 Tewari A, Narayan P. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: Interactions with antihypertensive therapy. Urology 1999; 53 (Suppl 3A): 14-20
16. 16 Eri LM, Tveter KJ. α-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923-34
17. 17 Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406-13
18. 18 Lepor H, Kaplan SA, Klimberg I et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525-30
19. 19 Schulman CC, Lock TMTW, Buzelin J-M. Tamsulosin: 3-year follow-up of efficacy and safety in 516 patients with LUTS suggestive of BPO. J Urol 1998; 159 (Suppl 5): 256, A983
20. 20 Boyle P, Gould AL, Roehrborn CG. Prostate, predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
21. 21 Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998; 160: 1358-67
22. 22 Masumori N, Tsukamoto T, Kumamoto Y et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: Results of community based studies in 2 countries. J Urol 1996; 155: 1324-7
23. 23 Gerber GS. The role of urodynamic study in the evaluation and management of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 1996; 48: 668-75
24. 24 Jensen KM-E, Jorgensen JB, Mogensen P. Prognostic value of pressure-flow study combined with stop-flow test. Scand J Urol Nephrol 1988; Suppl. 114: 72-7
25. 25 Neal DE, Ramsden PD, Sharples L et al. Outcome of elective prostatectomy. Br Med J 1989; 299: 762-7
26. 26 Robertson AS, Griffiths C, Neal DE. Conventional urodynamics and ambulatory monitoring in the definition and management of bladder outflow obstruction. J Urol 1996; 155: 506-11
27. 27 Sundin T, Dahlstrom A, Norlen L, Svedmyr N. The sympathetic innervation and adrenoceptor function of the human lower urinary tract in the normal state and after parasympathetic denervation. Invest Urol 1977; 14: 322-8
28. 28 McGuire EJ, Savastano JA. Effect of alpha-adrenergic blockade and anticholinergic agents on the decentralized primate bladder. Neurourol Urodyn 1985; 4: 139-42
29. 29 Swierzewski SJ, Gormley EA, Belville WD, Sweetser PM, Wan J, McGuire EJ. The effect of terazosin on bladder function in the spinal cord injured patient. J Urol 1994; 151: 951-4
30. 30 Koyanagi T, Takamatsu T, Taniguchi K. Further characterization of the external urethral sphincter in spinal cord injury: Study during spinal shock and evolution of responsiveness to alpha-adrenergic stimulation. J Urol 1984; 131: 1122-6
31. 31 Kakizaki H, Koyanagi T, Shinno Y, Kobayashi S, Matsumura K, Kato M. An electromyographic study on the urethral rhabdosphincter in normal and chronically rhizotomized cats: analysis of electrical potentials evoked by sympathetic nerve stimulation. J Urol 1994; 151: 238-43
32. 32 Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder: A placebo controlled double-blind study. J Urol 1996; 156: 1125-30
33. 33 Yamanishi T, Yasuda K, Homma Y, Kawabe K, Morita T. A multicenter placebo-controlled, double-blind trial of urapidil, an α-blocker, on neurogenic bladder dysfunction. Eur Urol 1999; 35: 45-51